
浏览全部资源
扫码关注微信
400042 重庆,陆军军医大学(第三军医大学)大坪医院临床营养科
[许红霞,E-mail: hx_xu2015@163.com XU Hongxia, E-mail: hx_xu2015@163.com
收稿:2021-04-02,
修回:2021-06-09,
纸质出版:2021-10-15
移动端阅览
张耀文, 卢宗亮, 李龙, 等. 索拉非尼联合麦冬皂苷D'共同抑制ERK和AKT通路促进PC3细胞凋亡[J]. 第三军医大学学报, 2021,43(19):1870-1876.
Yaowen ZHANG, Zongliang LU, Long LI, et al. Sorafenib combined with ophiopogonin D' inhibits ERK and AKT pathways to promote apoptosis in androgen-independent prostate cancer PC3 cells[J]. Journal of Third Military Medical University, 2021, 43(19): 1870-1876.
张耀文, 卢宗亮, 李龙, 等. 索拉非尼联合麦冬皂苷D'共同抑制ERK和AKT通路促进PC3细胞凋亡[J]. 第三军医大学学报, 2021,43(19):1870-1876. DOI: 10.16016/j.1000-5404.202104011.
Yaowen ZHANG, Zongliang LU, Long LI, et al. Sorafenib combined with ophiopogonin D' inhibits ERK and AKT pathways to promote apoptosis in androgen-independent prostate cancer PC3 cells[J]. Journal of Third Military Medical University, 2021, 43(19): 1870-1876. DOI: 10.16016/j.1000-5404.202104011.
目的
2
探讨索拉非尼(sorafenib
Sor)联合麦冬皂苷D'(Ophiopogonin D',OPD')对雄激素非依赖前列腺癌细胞(PC3细胞)的抗肿瘤效应及其机制。
方法
2
在体外实验中,Western blot检测不同浓度的OPD' (0、1.0、2.5、5.0 μmol/L)、Sor(0、2.5、5.0、10.0 μmol/L)、OPD' (2.5 μmol/L)+Sor(5.0 μmol/L)联合使用24 h后,对PC3细胞AKT、p-AKT、ERK、p-ERK表达的影响;流式细胞仪Annexin V-FITC和PI双染检测细胞凋亡。在体内实验中,构建PC3细胞异种移植瘤模型后,将裸鼠分为对照组、OPD' 组(1.0 mg/kg)、Sor组(2.5 mg/kg)、OPD' +Sor联合使用组并进行相应干预,且每3天测量裸鼠体质量和肿瘤体积,至药物干预21 d。
结果
2
Sor主要下调p-AKT蛋白表达及p-AKT/AKT水平(
P
<
0.05),仅在10.0 μmol/L时,降低p-ERK/ERK水平(
P
<
0.05)。OPD' 主要下调p-ERK蛋白的表达及p-ERK/ERK水平(
P
<
0.05),仅在5.0 μmol/L时
降低p-AKT/AKT水平(
P
<
0.05)。2.5 μmol/L OPD' 和5.0 μmol/L Sor联用时,p-AKT和p-ERK的蛋白表达及p-AKT/AKT和p-ERK/ERK水平均显著降低(
P
<
0.05)。细胞凋亡检测结果显示: 两药联用组的凋亡指数明显高于OPD' 或Sor单独用药组(
P
<
0.05)。体内实验结果显示: 1.0 mg/kg OPD' 和2.5 mg/kg Sor联用组肿瘤体积和质量均低于其他组(
P
<
0.05)。
结论
2
索拉非尼联合麦冬皂苷D' 通过抑制ERK和AKT通路,促进雄激素非依赖前列腺癌细胞凋亡。
Objective
2
To investigate the anti-tumor effect of sorafenib (Sor) combined with Ophiopogonin D'(OPD') on androgen-independent prostate cancer (PC3) cells and its mechanism.
Methods
2
In vitro
the exp
ression of AKT
p-AKT
ERK and p-ERK in PC3 cells was detected by Western blotting in 24 h after being treated with different concentrations of OPD' (0
1
2.5 and 5.0 μmol/L)
Sor (0
2.5
5.0 and 10.0 μmol/L) and OPD' (2.5 μmol/L)+Sor (5.0 μmol/L)
respectively. Apoptosis of PC3 cells was observed by flow cytometry with AnnexinV-FITC and propidium iodide (PI) double staining.
In vivo
PC3 cells xenograft tumor model was constructed in nude mice. Subsequently
24 nude mice were equally divided into control group
OPD' group (1.0 mg/kg)
Sor group (2.5 mg/kg) and OPD' +Sor combined group. The body weight of nude mice and the tumor volume were measured and recorded every 3 days until 21 d after drug intervention.
Results
2
Sor mainly down-regulated the expression levels of p-AKT and p-AKT/AKT (
P
<
0.05)
and only decreased p-ERK/ERK level at the concentration of 10.0 μmol/L (
P
<
0.05). While OPD' primarily down-regulated p-ERK and p-ERK/ERK levels (
P
<
0.05)
and only reduced p-AKT/AKT at 5.0 μmol/L (
P
<
0.05). However
the protein levels of p-AKT
p-ERK
p-AKT/AKT
and p-ERK/ERK were all greatly diminished in the combined group (2.5 μmol/L OPD' +5.0 μmol/L Sor) (
P
<
0.05). In addition
the apoptotic index was significantly higher in the combined group than the OPD' or Sor alone group (
P
<
0.05). The results of
in vivo
experiments also showed that the tumor volume and tumor weight in the combined group (1.0 mg/kg OPD' +2.5 mg/kg Sor) were much lower than those in the other groups (
P
<
0.05).
Conclusion
2
Sor combined with OPD' promotes apoptosis in PC3 cells by inhibiting ERK and Akt pathways.
FERLAY J, COLOMBET M, SOERJOMATARAM I, et al . Cancer statistics for the year 2020: an overview[J ] . Int J Cancer, 2021. [Published online ahead of print ] . DOI: 10.1002/ijc.33588.
CARVER B S, CHAPINSKI C, WONGVIPAT J, et al . Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer[J ] . Cancer Cell, 2011, 19(5): 575-586. DOI:10.1016/j.ccr.2011.04.008.
TOREN P, ZOUBEIDI A. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities(review)[J]. Int J Oncol, 2014, 45(5): 1793-1801. DOI:10.3892/ijo.2014.2601.
YU S W, SHEN G X, KHOR T O, et al . Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism[J ] . Mol Cancer Ther, 2008, 7(9): 2609-2620. DOI:10.1158/1535-7163.MCT-07-2400.
BUTLER D E, MARLEIN C, WALKER H F, et al . Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Ra f/MEK/ERK signalling in prostate cancer[J ] . Oncotarget,2017, 8(34): 56698-56713. DOI:10.18632/oncotarget.18082.
GAN Y, SHI C, INGE L, et al . Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells[J ] . Oncogene, 2010, 29(35): 4947-4958. DOI:10.1038/onc.2010.240.
OH S J, ERB H H, HOBISCH A, et al . Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways[J ] . Endocr Relat Cancer, 2012, 19(3): 305-319. DOI:10.1530/ERC-11-0298.
KINKADE C W, CASTILLO-MARTIN M, PUZIO-KUTER A, et al . Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model[J ] . J Clin Invest, 2008, 118(9): 3051-3064. DOI:10.1172/JCI34764.
LU Z L, WANG H, ZHU M X, et al . Ophiopogonin D', a natural product from Radix ophiopogonis, induces in vitro and in vivo RIPK 1 -dependent and caspase-independent apoptotic death in androgen-independent human prostate cancer cells[J ] . Front Pharmacol, 2018, 9: 432. DOI:10.3389/fphar.2018.00432..
QIAN J C, JIANG F R, WANG B, et al . Ophiopogonin D prevents H 2 O 2 -induced injury in primary human umbilical vein endothelial cells[J ] . J Ethnopharmacol, 2010, 128(2): 438-445. DOI:10.1016/j.jep.2010.01.031..
SHENG X, YANG Y, LIU J, et al . Ophiopogonin A alleviates hemorrhagic shock-induced renal injury via induction of Nrf2 expression[J ] . Front Physiol, 2020, 11(619740. DOI: 10.3389/fphys.2020.619740..
ZHONG Y, LIN Z, LU J, et al . CCL2-CCL5/CCR4 contributed to radiation-induced epithelial-mesenchymal transition of HPAEpiC cells via the ERK signaling pathways[J ] . Am J Transl Res, 2019, 11(2): 733-743..
LUO J, WANG D, WAN X C, et al . Crosstalk between AR and wnt signaling promotes castration-resistant prostate cancer growth[J ] . Onco Targets Ther, 2020, 13: 9257-9267. DOI:10.2147/OTT.S245861.
ABD W N, LAJIS N H, ABAS F, et al . Mechanism of anti-cancer activity of curcumin on androgen-dependent and androgen-independent prostate cancer[J ] . Nutrients, 2020, 12(3): DOI:10.3390/nu12030679.
DE BONO J S, DE GIORGI U, RODRIGUES D N, et al . Randomized phase Ⅱ study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss[J ] . Clin Cancer Res, 2019, 25(3): 928-936. DOI:10.1158/1078-0432.CCR-18-0981.
TEE, SUSTER I, TRUONG S, et al . Targeted AKT inhibition in prostate cancer cells and spheroids reduces aerobic glycolysis and generation of hyperpolarized [1- 13 C ] lactate[J ] . Mol Cancer Res, 2018, 16(3): 453-460. DOI:10.1158/1541-7786.MCR-17-0458..
ESCUDIER B, WORDEN F, KUDO M. Sorafenib: key lessons from over 10 years of experience[J]. Expert Rev Anticancer Ther, 2019, 19(2): 177-189. DOI:10.1080/14737140.2019.1559058.
BURCHERT A, BUG G, FRITZ L V, et al . Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)[J ] . J Clin Oncol, 2020, 38(26): 2993-3002. DOI:10.1200/JCO.19.03345.
NICKOLS N G, NAZARIAN R, ZHAO S G, et al . MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer[J ] . Prostate Cancer Prostatic Di s, 2019, 22(4): 531-538. DOI:10.1038/s41391-019-0134-5.
SUTHIPHONGCHAI T, PHIMSEN S, SAKULKHU U, et al . PD98059-inhibited invasion of Dunning rat prostate cancer cells involves suppression of motility but not MMP-2 or uPA secretion[J ] . Oncol Rep, 2006, 15(6): 1605-1610. DOI:10.3892/or.15.6.1605.
CHEN P S, SHIH Y W, HUANG H C, et al . Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression[J ] . PLoS ONE, 2011, 6(5): e20164. DOI:10.1371/journal.pone.0020164.
沈岚, 徐德生, 冯怡, 等. 大鼠肠内菌对麦冬皂苷D'代谢的研究[J]. 中国中药杂志, 2005, 30(8): 618-620.
SHEN L, XU D S, FENG Y, et al . Effect of intestinal bacteria on metabolism of ophiopognin saponin D' in rats[J ] . China J Chin Mater Med, 2005, 30(8): 618-620.
CHEN B N, ZHOU S K, ZHAN Y J, et al . Dioscin inhibits the invasion and migration of hepatocellular carcinoma HepG2 cells by reversing TGF-β1-induced epithelial-mesenchymal transition[J ] . Molecules, 2019, 24(12): E2222. DOI:10.3390/molecules24122222.
SI L L, ZHENG L L, XU L N, et al . Dioscin suppresses human laryngeal cancer cells growth via induction of cell-cycle arrest and MAPK-mediated mitochondrial-derived apoptosis and inhibition of tumor invasion[J ] . Eur J Pharmacol, 2016, 774: 105-117. DOI:10.1016/j.ejphar.2016.02.009.
ZHANG Y Y, HAN Y W, ZHAI K F, et al . Ophiopogonin-D suppresses MDA-MB-435 cell adhesion and invasion by inhibiting matrix metalloproteinase-9[J ] . Mol Med Rep, 2015, 12(1): 1493-1498. DOI:10.3892/mmr.2015.3541.
CAO Z, LIAO Q J, SU M, et al . AKT and ERK dual inhibitors: The way forward? [J ] . Cancer Lett, 2019, 459: 30-40. DOI:10.1016/j.canlet.2019.05.025.
KIM K Y, PARK K I, KIM S H, et al . Inhibition of autophagy promotes salinomycin-induced apoptosis via reactive oxygen species-mediated PI3K/AKT/mTOR and ERK/p38 MAPK-dependent signaling in human prostate cancer cells[J ] . Int J Mol Sci, 2017, 18(5): E1088. DOI:10.3390/ijms18051088.
FAN L X, HE Z L, HEAD S A, et al . Clofoctol and sorafenib inhibit prostate cancer growth via synergistic induction of endoplasmic reticulum stress and UPR pathways[J ] . Cancer Manag Res, 2018, 10: 4817-4829. DOI:10.2147/CMAR.S175256..
KIM S M, LEE S Y, CHO J S, et al . Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB[J ] . Eur J Pharmacol, 2010, 631(1/2/3): 1-9. DOI:10.1016/j.ejphar.2009.12.018..
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621